[144] Xeris Biopharma Holdings, Inc. SEC Filing
Xeris Biopharma (XERS) submitted a Form 144 notice proposing the sale of 107,500 shares of common stock, with an aggregate market value of $786,451.77, to be offered through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 08/13/2025. The filing lists 161,480,367 shares outstanding and discloses three restricted-stock acquisition lots: 15,000 shares on 06/07/2023, 42,500 on 06/05/2024, and 50,000 on 06/04/2025. No securities of the issuer were reported sold in the past three months. The notice includes the standard certification that the seller does not possess undisclosed material information and references Rule 10b5-1 trading plans.
Xeris Biopharma (XERS) ha presentato un avviso Form 144 proponendo la vendita di 107,500 azioni ordinarie, per un valore di mercato complessivo di $786,451.77, da offrire tramite Morgan Stanley Smith Barney LLC sul NASDAQ con data approssimativa di vendita 08/13/2025. La comunicazione indica 161,480,367 azioni in circolazione e riporta tre lotti di acquisto di azioni soggette a restrizioni: 15,000 azioni il 06/07/2023, 42,500 il 06/05/2024 e 50,000 il 06/04/2025. Non risultano titoli dell'emittente venduti negli ultimi tre mesi. L'avviso include la certificazione standard che il venditore non 猫 in possesso di informazioni rilevanti non divulgate e fa riferimento ai piani di negoziazione ai sensi della Regola 10b5-1.
Xeris Biopharma (XERS) present贸 un aviso Form 144 proponiendo la venta de 107,500 acciones ordinarias, con un valor de mercado agregado de $786,451.77, que se ofrecer谩n a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ con una fecha aproximada de venta de 08/13/2025. La presentaci贸n registra 161,480,367 acciones en circulaci贸n y revela tres lotes de adquisici贸n de acciones sujetas a restricciones: 15,000 acciones el 06/07/2023, 42,500 el 06/05/2024 y 50,000 el 06/04/2025. No se reportaron valores del emisor vendidos en los 煤ltimos tres meses. El aviso incluye la certificaci贸n est谩ndar de que el vendedor no posee informaci贸n material no divulgada y hace referencia a los planes de negociaci贸n conforme a la Regla 10b5-1.
Xeris Biopharma (XERS)電� Form 144 韱奠靹滊ゼ 鞝滌稖頃橃棳 氤错喌欤� 107,500欤茧ゼ 毵り皝頃� 瓴冹潉 鞝滌晥頄堨溂氅�, 齑� 鞁滉皜鞎§潃 $786,451.77鞚搓碃 Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐� 鞝滌晥霅� 鞓堨爼鞚措┌ 鞓堨儊 毵り皝鞚检潃 08/13/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞙犿喌 欤检嫕靾� 161,480,367欤缄皜 旮办灛霅橃柎 鞛堨溂氅� 鞝滍暅欤� 旆摑瓿� 甏�霠悳 靹� 瓯挫潣 霝忟澊 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 15,000欤�(06/07/2023), 42,500(06/05/2024), 50,000(06/04/2025). 歆�雮� 3臧滌洈 霃欖晥 氚滍枆靷潣 歃濌秾鞚� 毵る弰霅橃棃雼る姅 氤搓碃電� 鞐嗢姷雼堧嫟. 韱奠靹滌棎電� 毵る弰鞛愱皜 牍勱车臧� 欷戩殧 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑 氍戈惮臧� 韽暔霅橃柎 鞛堨溂氅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 雽�頃� 鞏戈笁霃� 鞛堨姷雼堧嫟.
Xeris Biopharma (XERS) a d茅pos茅 un avis Form 144 proposant la vente de 107,500 actions ordinaires, pour une valeur de march茅 globale de $786,451.77, qui seront propos茅es par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, avec une date de vente approximative indiqu茅e au 08/13/2025. Le d茅p么t mentionne 161,480,367 actions en circulation et d茅voile trois lots d'acquisition d'actions restreintes : 15,000 actions le 06/07/2023, 42,500 le 06/05/2024 et 50,000 le 06/04/2025. Aucun titre de l'茅metteur n'a 茅t茅 signal茅 comme vendu au cours des trois derniers mois. L'avis comprend la certification standard selon laquelle le vendeur ne dispose pas d'informations mat茅rielles non divulgu茅es et fait r茅f茅rence aux plans de n茅gociation en vertu de la r猫gle 10b5-1.
Xeris Biopharma (XERS) hat eine Form鈥�144鈥慚itteilung eingereicht, in der der Verkauf von 107,500 Stammaktien mit einem Gesamtmarktwert von $786,451.77 vorgeschlagen wird, die 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ angeboten werden sollen; das ungef盲hre Verkaufsdatum wird mit 08/13/2025 angegeben. Die Einreichung nennt 161,480,367 ausstehende Aktien und weist auf drei beschr盲nkte Erwerbslots hin: 15,000 Aktien am 06/07/2023, 42,500 am 06/05/2024 und 50,000 am 06/04/2025. In den vergangenen drei Monaten wurden keine Wertpapiere des Emittenten als verkauft gemeldet. Die Mitteilung enth盲lt die 眉bliche Best盲tigung, dass der Verk盲ufer keine nicht offengelegten wesentlichen Informationen besitzt, und verweist auf Handelspl盲ne nach Rule 10b5-1.
- None.
- None.
Insights
TL;DR: Routine Form 144 notice for a sub-1% proposed sale; no past three-month sales reported.
The filing documents a proposed sale of 107,500 common shares valued at $786,451.77 to be executed via Morgan Stanley on NASDAQ on or about 08/13/2025. The filing identifies three restricted-stock grants as the source of the shares, with acquisition dates in 2023, 2024 and 2025. The filer reports Nothing to Report for sales in the prior three months and includes the standard representation about absence of undisclosed material information. Based on the disclosed numbers, this appears to be a routine Form 144 notification rather than a material market-moving event.
TL;DR: Disclosure is consistent with Rule 144 mechanics; key seller identity is not provided in the visible fields.
The notice specifies the broker, the class of security, quantities, aggregate market value and acquisition details for restricted stock lots but does not provide a named seller in the visible content. The filing reiterates the signatory's certification about lacking material nonpublic information and mentions trading-plan provisions. For governance review, the document supplies transaction-level detail required by Rule 144 but omits explicit filer identifier details in the provided text, which limits assessment of insider status or related party implications.
Xeris Biopharma (XERS) ha presentato un avviso Form 144 proponendo la vendita di 107,500 azioni ordinarie, per un valore di mercato complessivo di $786,451.77, da offrire tramite Morgan Stanley Smith Barney LLC sul NASDAQ con data approssimativa di vendita 08/13/2025. La comunicazione indica 161,480,367 azioni in circolazione e riporta tre lotti di acquisto di azioni soggette a restrizioni: 15,000 azioni il 06/07/2023, 42,500 il 06/05/2024 e 50,000 il 06/04/2025. Non risultano titoli dell'emittente venduti negli ultimi tre mesi. L'avviso include la certificazione standard che il venditore non 猫 in possesso di informazioni rilevanti non divulgate e fa riferimento ai piani di negoziazione ai sensi della Regola 10b5-1.
Xeris Biopharma (XERS) present贸 un aviso Form 144 proponiendo la venta de 107,500 acciones ordinarias, con un valor de mercado agregado de $786,451.77, que se ofrecer谩n a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ con una fecha aproximada de venta de 08/13/2025. La presentaci贸n registra 161,480,367 acciones en circulaci贸n y revela tres lotes de adquisici贸n de acciones sujetas a restricciones: 15,000 acciones el 06/07/2023, 42,500 el 06/05/2024 y 50,000 el 06/04/2025. No se reportaron valores del emisor vendidos en los 煤ltimos tres meses. El aviso incluye la certificaci贸n est谩ndar de que el vendedor no posee informaci贸n material no divulgada y hace referencia a los planes de negociaci贸n conforme a la Regla 10b5-1.
Xeris Biopharma (XERS)電� Form 144 韱奠靹滊ゼ 鞝滌稖頃橃棳 氤错喌欤� 107,500欤茧ゼ 毵り皝頃� 瓴冹潉 鞝滌晥頄堨溂氅�, 齑� 鞁滉皜鞎§潃 $786,451.77鞚搓碃 Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐� 鞝滌晥霅� 鞓堨爼鞚措┌ 鞓堨儊 毵り皝鞚检潃 08/13/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞙犿喌 欤检嫕靾� 161,480,367欤缄皜 旮办灛霅橃柎 鞛堨溂氅� 鞝滍暅欤� 旆摑瓿� 甏�霠悳 靹� 瓯挫潣 霝忟澊 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 15,000欤�(06/07/2023), 42,500(06/05/2024), 50,000(06/04/2025). 歆�雮� 3臧滌洈 霃欖晥 氚滍枆靷潣 歃濌秾鞚� 毵る弰霅橃棃雼る姅 氤搓碃電� 鞐嗢姷雼堧嫟. 韱奠靹滌棎電� 毵る弰鞛愱皜 牍勱车臧� 欷戩殧 鞝曤炒毳� 氤挫湢頃橁碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑 氍戈惮臧� 韽暔霅橃柎 鞛堨溂氅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 雽�頃� 鞏戈笁霃� 鞛堨姷雼堧嫟.
Xeris Biopharma (XERS) a d茅pos茅 un avis Form 144 proposant la vente de 107,500 actions ordinaires, pour une valeur de march茅 globale de $786,451.77, qui seront propos茅es par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, avec une date de vente approximative indiqu茅e au 08/13/2025. Le d茅p么t mentionne 161,480,367 actions en circulation et d茅voile trois lots d'acquisition d'actions restreintes : 15,000 actions le 06/07/2023, 42,500 le 06/05/2024 et 50,000 le 06/04/2025. Aucun titre de l'茅metteur n'a 茅t茅 signal茅 comme vendu au cours des trois derniers mois. L'avis comprend la certification standard selon laquelle le vendeur ne dispose pas d'informations mat茅rielles non divulgu茅es et fait r茅f茅rence aux plans de n茅gociation en vertu de la r猫gle 10b5-1.
Xeris Biopharma (XERS) hat eine Form鈥�144鈥慚itteilung eingereicht, in der der Verkauf von 107,500 Stammaktien mit einem Gesamtmarktwert von $786,451.77 vorgeschlagen wird, die 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ angeboten werden sollen; das ungef盲hre Verkaufsdatum wird mit 08/13/2025 angegeben. Die Einreichung nennt 161,480,367 ausstehende Aktien und weist auf drei beschr盲nkte Erwerbslots hin: 15,000 Aktien am 06/07/2023, 42,500 am 06/05/2024 und 50,000 am 06/04/2025. In den vergangenen drei Monaten wurden keine Wertpapiere des Emittenten als verkauft gemeldet. Die Mitteilung enth盲lt die 眉bliche Best盲tigung, dass der Verk盲ufer keine nicht offengelegten wesentlichen Informationen besitzt, und verweist auf Handelspl盲ne nach Rule 10b5-1.
FAQ
How many XERS shares are proposed for sale in this Form 144?
When and where is the proposed sale expected to occur for XERS shares?
What acquisition details does the Form 144 provide for the XERS shares to be sold?
Were any XERS securities sold by the seller in the past three months according to the filing?
Does the Form 144 indicate whether the seller has undisclosed material information?
Who is the named seller of the XERS shares in this Form 144?
